DGIdb - GEMCITABINE Drug Record

GEMCITABINE chembl:CHEMBL888 ApprovedAntineoplasticImmunotherapy

Alternate Names:

GEMZAR
LY188011
GEMCITABINE
NSC-613327
LY-188011
2',2'-DIFLUORODEOXYCYTIDINE
4-AMINO-1-((2R,4R,5R)-3,3-DIFLUORO-4-HYDROXY-5-(HYDROXYMETHYL)-TETRAHYDROFURAN-2-YL)PYRIMIDIN-2(1H)-ONE
GEMCITABIN
GEMCITABINA
GEMZAR®
2'-DEOXY-2',2'-DIFLUOROCYTIDINE
GEMCITABINUM
GEMCITABINE HYDROCHLORIDE
chembl:CHEMBL888
pubchem.compound:60750
chemidplus:95058-81-4
rxcui:12574
drugbank:00441

Drug Info:

FDA Approval	approved
Drug Class	Small Molecule
Drug Indications	antineoplastic agent

(6 More Sources)

Publications:

Kim et al., 2016, Gemcitabine Plus Radiation Therapy for High-Grade Glioma: Long-Term Results of a Phase 1 Dose-Escalation Study., Int. J. Radiat. Oncol. Biol. Phys.
Knights J et al., 2014, Genetic factors associated with gemcitabine pharmacokinetics, disposition, and toxicity., Pharmacogenet Genomics
Woo HI et al., 2012, Effect of genetic polymorphisms on therapeutic response and clinical outcomes in pancreatic cancer patients treated with gemcitabine., Pharmacogenomics
Infante et al., 2017, Phase I Study of GDC-0425, a Checkpoint Kinase 1 Inhibitor, in Combination with Gemcitabine in Patients with Refractory Solid Tumors., Clin. Cancer Res.
Osborne et al., 2016, Multiparameter Lead Optimization to Give an Oral Checkpoint Kinase 1 (CHK1) Inhibitor Clinical Candidate: (R)-5-((4-((Morpholin-2-ylmethyl)amino)-5-(trifluoromethyl)pyridin-2-yl)amino)pyrazine-2-carbonitrile (CCT245737)., J. Med. Chem.
Vena et al., 2015, The MEK1/2 Inhibitor Pimasertib Enhances Gemcitabine Efficacy in Pancreatic Cancer Models by Altering Ribonucleotide Reductase Subunit-1 (RRM1)., Clin. Cancer Res.
Rajeshkumar et al., 2011, MK-1775, a potent Wee1 inhibitor, synergizes with gemcitabine to achieve tumor regressions, selectively in p53-deficient pancreatic cancer xenografts., Clin. Cancer Res.
Kreahling et al., 2013, Wee1 inhibition by MK-1775 leads to tumor inhibition and enhances efficacy of gemcitabine in human sarcomas., PLoS ONE
Björn N et al., 2020, Genes and variants in hematopoiesis-related pathways are associated with gemcitabine/carboplatin-induced thrombocytopenia., Pharmacogenomics J
Bellmunt J et al., 2007, Gene expression of ERCC1 as a novel prognostic marker in advanced bladder cancer patients receiving cisplatin-based chemotherapy., Ann Oncol
Ceppi P et al., 2006, ERCC1 and RRM1 gene expressions but not EGFR are predictive of shorter survival in advanced non-small-cell lung cancer treated with cisplatin and gemcitabine., Ann Oncol
Liu et al., 2015, WEE1 kinase polymorphism as a predictive biomarker for efficacy of platinum-gemcitabine doublet chemotherapy in advanced non-small cell lung cancer patients., Sci Rep
Alvarellos ML et al., 2014, PharmGKB summary: gemcitabine pathway., Pharmacogenet Genomics
Liu ZQ et al., 2014, Prognostic value of human equilibrative nucleoside transporter1 in pancreatic cancer receiving gemcitabin-based chemotherapy: a meta-analysis., PLoS One
Lee SY et al., 2014, Genetic polymorphisms of SLC28A3, SLC29A1 and RRM1 predict clinical outcome in patients with metastatic breast cancer receiving gemcitabine plus paclitaxel chemotherapy., Eur J Cancer
Maréchal R et al., 2012, Levels of gemcitabine transport and metabolism proteins predict survival times of patients treated with gemcitabine for pancreatic adenocarcinoma., Gastroenterology
Tanaka M et al., 2010, Gemcitabine metabolic and transporter gene polymorphisms are associated with drug toxicity and efficacy in patients with locally advanced pancreatic cancer., Cancer
Safran et al., 2004, Herceptin and gemcitabine for metastatic pancreatic cancers that overexpress HER-2/neu., Cancer Invest.
Maring et al., 2005, Genetic factors influencing pyrimidine-antagonist chemotherapy., Pharmacogenomics J.
Vernejoul et al., 2006, Gene therapy based on gemcitabine chemosensitization suppresses pancreatic tumor growth., Mol. Ther.
Lam et al., 2007, The impact of hypoxic treatment on the expression of phosphoglycerate kinase and the cytotoxicity of troxacitabine and gemcitabine., Mol. Pharmacol.
Hsu et al., 2005, Phosphorylation of Cytidine, Deoxycytidine, and Their Analog Monophosphates by Human UMP/CMP Kinase Is Differentially Regulated by ATP and Magnesium., Mol. Pharmacol.
Ryu JS et al., 2011, Differential effect of polymorphisms of CMPK1 and RRM1 on survival in advanced non-small cell lung cancer patients treated with gemcitabine or taxane/cisplatinum., J Thorac Oncol
Mitra AK et al., 2012, Pathway-based pharmacogenomics of gemcitabine pharmacokinetics in patients with solid tumors., Pharmacogenomics
Ellsworth KA et al., 2013, Contribution of FKBP5 genetic variation to gemcitabine treatment and survival in pancreatic adenocarcinoma., PLoS One
Brown CC et al., 2014, Genome-wide association and pharmacological profiling of 29 anticancer agents using lymphoblastoid cell lines., Pharmacogenomics
Kadera et al., 2015, Low expression of the E3 ubiquitin ligase CBL confers chemoresistance in human pancreatic cancer and is targeted by epidermal growth factor receptor inhibition., Clin. Cancer Res.
Khatri A et al., 2014, SLC28A3 genotype and gemcitabine rate of infusion affect dFdCTP metabolite disposition in patients with solid tumours., Br J Cancer
Angevin et al., 2017, Safety, tolerability and antitumour activity of LY2780301 (p70S6K/AKT inhibitor) in combination with gemcitabine in molecularly selected patients with advanced or metastatic cancer: a phase IB dose escalation study., Eur. J. Cancer
Cui et al., 2012, Genetically defined subsets of human pancreatic cancer show unique in vitro chemosensitivity., Clin. Cancer Res.
Ziemke M et al., 2017, Reduced Smad4 expression and DNA topoisomerase inhibitor chemosensitivity in non-small cell lung cancer., Lung Cancer
Innocenti F et al., 2019, An initial genetic analysis of gemcitabine-induced high-grade neutropenia in pancreatic cancer patients in CALGB 80303 (Alliance)., Pharmacogenet Genomics
Soo RA et al., 2009, Distribution of gemcitabine pathway genotypes in ethnic Asians and their association with outcome in non-small cell lung cancer patients., Lung Cancer
Yang Z et al., 2018, Somatic FGFR3 Mutations Distinguish a Subgroup of Muscle-Invasive Bladder Cancers with Response to Neoadjuvant Chemotherapy., EBioMedicine
Fedier et al., 2003, The effect of loss of Brca1 on the sensitivity to anticancer agents in p53-deficient cells., Int. J. Oncol.
O'Reilly EM et al., 2018, Phase 1 trial evaluating cisplatin, gemcitabine, and veliparib in 2 patient cohorts: Germline BRCA mutation carriers and wild-type BRCA pancreatic ductal adenocarcinoma., Cancer
Qian J et al., 2012, Association of CASP7 polymorphisms and survival of patients with non-small cell lung cancer with platinum-based chemotherapy treatment., Chest
Leone et al., 2016, Panitumumab in combination with gemcitabine and oxaliplatin does not prolong survival in wild-type KRAS advanced biliary tract cancer: A randomized phase 2 trial (Vecti-BIL study)., Cancer
Van Laethem et al., 2017, Phase I/II Study of Refametinib (BAY 86-9766) in Combination with Gemcitabine in Advanced Pancreatic cancer., Target Oncol
O'Neil et al., 2015, A phase II/III randomized study to compare the efficacy and safety of rigosertib plus gemcitabine versus gemcitabine alone in patients with previously untreated metastatic pancreatic cancer., Ann. Oncol.
Mahalingam et al., 2015, The combination of intravenous Reolysin and gemcitabine induces reovirus replication and endoplasmic reticular stress in a patient with KRAS-activated pancreatic cancer., BMC Cancer
Infante et al., 2014, A randomised, double-blind, placebo-controlled trial of trametinib, an oral MEK inhibitor, in combination with gemcitabine for patients with untreated metastatic adenocarcinoma of the pancreas., Eur. J. Cancer
Kim et al., 2011, Impact of KRAS mutations on clinical outcomes in pancreatic cancer patients treated with first-line gemcitabine-based chemotherapy., Mol. Cancer Ther.
Labroli MA et al., 2014, The identification of novel 5'-amino gemcitabine analogs as potent RRM1 inhibitors., Bioorg Med Chem
Kwon et al., 2006, Ribonucleotide reductase M1 (RRM1) 2464G>A polymorphism shows an association with gemcitabine chemosensitivity in cancer cell lines., Pharmacogenet. Genomics
Smid et al., 2006, Micro-array analysis of resistance for gemcitabine results in increased expression of ribonucleotide reductase subunits., Nucleosides Nucleotides Nucleic Acids
Bepler et al., 2006, RRM1 modulated in vitro and in vivo efficacy of gemcitabine and platinum in non-small-cell lung cancer., J. Clin. Oncol.
Cerqueira et al., 2007, Understanding ribonucleotide reductase inactivation by gemcitabine., Chemistry
Rosell et al., 2006, Pharmacogenomics and gemcitabine., Ann. Oncol.
Nakahira et al., 2007, Involvement of ribonucleotide reductase M1 subunit overexpression in gemcitabine resistance of human pancreatic cancer., Int. J. Cancer
Vilmar et al., 2013, Predictive impact of RRM1 protein expression on vinorelbine efficacy in NSCLC patients randomly assigned in a chemotherapy phase III trial., Ann. Oncol.
Dong et al., 2014, Response to first-line chemotherapy in patients with non-small cell lung cancer according to RRM1 expression., PLoS ONE
Akita et al., 2009, Significance of RRM1 and ERCC1 expression in resectable pancreatic adenocarcinoma., Oncogene
Nie et al., 2013, The tailored chemotherapy based on RRM1 immunohistochemical expression in patients with advanced non-small cell lung cancer., Cancer Biomark
Rosell R et al., 2004, Ribonucleotide reductase messenger RNA expression and survival in gemcitabine/cisplatin-treated advanced non-small cell lung cancer patients., Clin Cancer Res
Rosell R et al., 2004, Gene expression as a predictive marker of outcome in stage IIB-IIIA-IIIB non-small cell lung cancer after induction gemcitabine-based chemotherapy followed by resectional surgery., Clin Cancer Res
Hegde et al., 2013, Blocking NRG1 and other ligand-mediated Her4 signaling enhances the magnitude and duration of the chemotherapeutic response of non-small cell lung cancer., Sci Transl Med
Miyazawa et al., 2010, Phase I clinical trial using peptide vaccine for human vascular endothelial growth factor receptor 2 in combination with gemcitabine for patients with advanced pancreatic cancer., Cancer Sci.
Matthews et al., 2007, Pharmacological abrogation of S-phase checkpoint enhances the anti-tumor activity of gemcitabine in vivo., Cell Cycle
Li Y et al., 2011, Genetic variations in multiple drug action pathways and survival in advanced stage non-small cell lung cancer treated with chemotherapy., Clin Cancer Res
Lee et al., 2006, Epidermal growth factor receptor mutations and response to chemotherapy in patients with non-small-cell lung cancer., Jpn. J. Clin. Oncol.
van der Heijden et al., 2005, In vivo therapeutic responses contingent on Fanconi anemia/BRCA2 status of the tumor., Clin. Cancer Res.
Kroep et al., 2002, Pretreatment deoxycytidine kinase levels predict in vivo gemcitabine sensitivity., Mol. Cancer Ther.
Saliba J et al., 2016, Pharmacogenetic characterization of naturally occurring germline NT5C1A variants to chemotherapeutic nucleoside analogs., Pharmacogenet Genomics
Rosell et al., 2012, Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial., Lancet Oncol.
Zhou et al., 2011, Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study., Lancet Oncol.
Nam et al., 2016, Src as a Therapeutic Target in Biliary Tract Cancer., Mol. Cancer Ther.
Xu et al., 2016, CIP2A down regulation enhances the sensitivity of pancreatic cancer cells to gemcitabine., Oncotarget
Kiyotani K et al., 2012, A genome-wide association study identifies four genetic markers for hematological toxicities in cancer patients receiving gemcitabine therapy., Pharmacogenet Genomics
Baker JA et al., 2013, Pharmacogenomics of gemcitabine metabolism: functional analysis of genetic variants in cytidine deaminase and deoxycytidine kinase., Drug Metab Dispos
Sun et al., 2009, Polymorphisms in XRCC1 and XPG and response to platinum-based chemotherapy in advanced non-small cell lung cancer patients., Lung Cancer
Verma et al., 2006, Increased expression of tissue transglutaminase in pancreatic ductal adenocarcinoma and its implications in drug resistance and metastasis., Cancer Res.
Franco et al., 2014, CDK4/6 inhibitors have potent activity in combination with pathway selective therapeutic agents in models of pancreatic cancer., Oncotarget
McCaffery I et al., 2013, Putative predictive biomarkers of survival in patients with metastatic pancreatic adenocarcinoma treated with gemcitabine and ganitumab, an IGF1R inhibitor., Clin Cancer Res

GEMCITABINE CMPK1

Interaction Score: 2.29

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

PMIDs:
16041392 17000136 17565005 15550676 21642870 22838949 22838950 24361227

Sources:
PharmGKB
GEMCITABINE DAPK1

Interaction Score: 1.53

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
22293537

Sources:
PharmGKB
GEMCITABINE TENT4A

Interaction Score: 1.53

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
22838950

Sources:
PharmGKB
GEMCITABINE CIP2A

Interaction Score: 1.53

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
26894380

Sources:
CIViC
GEMCITABINE CDC5L

Interaction Score: 1.53

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
22838950

Sources:
PharmGKB
GEMCITABINE SH2D5

Interaction Score: 1.53

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
22838950

Sources:
PharmGKB
GEMCITABINE FHL2

Interaction Score: 1.53

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
24444404

Sources:
PharmGKB
GEMCITABINE DCTD

Interaction Score: 1.53

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
22838950

Sources:
PharmGKB
GEMCITABINE ALG10

Interaction Score: 1.53

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
24225399

Sources:
PharmGKB
GEMCITABINE RRM1

Interaction Score: 0.98

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Trial Name gemcitabine HCl,Gemzar

Novel drug target Established target

PMIDs:
24588962 16708051 17065054 16966686 17636467 16807441 17131328 23038758 24647522 19543324 24595080 14977831 15217961

Sources:
DTC ClearityFoundationBiomarkers TdgClinicalTrial ClearityFoundationClinicalTrial CIViC
GEMCITABINE CDSN

Interaction Score: 0.76

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
31616045

Sources:
PharmGKB
GEMCITABINE ETS2

Interaction Score: 0.76

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
31616045

Sources:
PharmGKB
GEMCITABINE DOCK8

Interaction Score: 0.76

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
31616045

Sources:
PharmGKB
GEMCITABINE MUCL3

Interaction Score: 0.76

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
31616045

Sources:
PharmGKB
GEMCITABINE SLC29A3

Interaction Score: 0.76

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
PharmGKB
GEMCITABINE PPP1R18

Interaction Score: 0.76

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
31616045

Sources:
PharmGKB
GEMCITABINE MSH5

Interaction Score: 0.76

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
31616045

Sources:
PharmGKB
GEMCITABINE NT5C

Interaction Score: 0.76

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
25162786

Sources:
PharmGKB
GEMCITABINE C6ORF15

Interaction Score: 0.76

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
31616045

Sources:
PharmGKB
GEMCITABINE XYLT2

Interaction Score: 0.76

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
31616045

Sources:
PharmGKB
GEMCITABINE ATAT1

Interaction Score: 0.76

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
31616045

Sources:
PharmGKB
GEMCITABINE SLC28A1

Interaction Score: 0.61

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
30889042 25162786 18538445

Sources:
PharmGKB
GEMCITABINE NT5C3A

Interaction Score: 0.51

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
22838949

Sources:
PharmGKB
GEMCITABINE GPX5

Interaction Score: 0.51

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
21636554

Sources:
PharmGKB
GEMCITABINE NT5C1A

Interaction Score: 0.51

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
26906009

Sources:
PharmGKB
GEMCITABINE PRRC2A

Interaction Score: 0.51

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
31616045

Sources:
PharmGKB
GEMCITABINE SLC29A2

Interaction Score: 0.51

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
25162786

Sources:
PharmGKB
GEMCITABINE HCP5

Interaction Score: 0.51

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
31616045

Sources:
PharmGKB
GEMCITABINE NT5C2

Interaction Score: 0.46

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
24300978 22838949

Sources:
PharmGKB
GEMCITABINE DCK

Interaction Score: 0.42

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
25162786 23230131 22705007 20665488 12477049

Sources:
PharmGKB
GEMCITABINE SLC29A1

Interaction Score: 0.42

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
25162786 24475233 24361227 22705007 20665488

Sources:
PharmGKB
GEMCITABINE SLC28A3

Interaction Score: 0.38

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
25162786 24300978

Sources:
PharmGKB
GEMCITABINE SLC28A2

Interaction Score: 0.38

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
20665488 18538445

Sources:
PharmGKB
GEMCITABINE POLR1G

Interaction Score: 0.38

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
PharmGKB
GEMCITABINE PSORS1C1

Interaction Score: 0.38

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
31616045

Sources:
PharmGKB
GEMCITABINE PPP1R13L

Interaction Score: 0.38

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
PharmGKB
GEMCITABINE SERPINA5

Interaction Score: 0.38

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
31616045

Sources:
PharmGKB
GEMCITABINE FANCC

Interaction Score: 0.31

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
16243825

Sources:
CIViC
GEMCITABINE CDA

Interaction Score: 0.25

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
12477049

Sources:
NCI
GEMCITABINE ACSS2

Interaction Score: 0.25

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
21636554

Sources:
PharmGKB
GEMCITABINE POLR2A

Interaction Score: 0.25

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
PharmGKB
GEMCITABINE SMAD4

Interaction Score: 0.25

Interaction Types & Directionality:

n/a

Interaction Info:

Evidence Type Actionable

Approval Status Preclinical

Response Type decreased response

PMIDs:
22753594 28577946

Sources:
JAX-CKB CIViC
GEMCITABINE CBL

Interaction Score: 0.25

Interaction Types & Directionality:

n/a

Interaction Info:

Evidence Type Emerging

Approval Status Preclinical - Cell line xenograft

Response Type predicted – sensitive

PMIDs:
25348515

Sources:
JAX-CKB
GEMCITABINE PPCDC

Interaction Score: 0.19

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
PharmGKB
GEMCITABINE KLC3

Interaction Score: 0.19

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
PharmGKB
GEMCITABINE ERCC1

Interaction Score: 0.18

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
17229776 16980606

Sources:
CIViC PharmGKB
GEMCITABINE ATRX

Interaction Score: 0.17

Interaction Types & Directionality:

n/a

Interaction Info:

combination therapy Gemcitabine + Radiotherapy

Indication/Tumor Type malignant glioma

Response Type predicted – sensitive

PMIDs:
26853339

Sources:
JAX-CKB
GEMCITABINE XRCC1

Interaction Score: 0.15

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
19157633

Sources:
CIViC
GEMCITABINE WEE1

Interaction Score: 0.15

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
26057002

Sources:
CIViC
GEMCITABINE HLA-C

Interaction Score: 0.13

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
31616045

Sources:
PharmGKB
GEMCITABINE FKBP5

Interaction Score: 0.13

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
23936393

Sources:
PharmGKB
GEMCITABINE RRM2

Interaction Score: 0.13

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

PMIDs:
None found

Sources:
ClearityFoundationClinicalTrial TTD
GEMCITABINE IGF2

Interaction Score: 0.11

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
23741071

Sources:
CIViC
GEMCITABINE RRM2B

Interaction Score: 0.08

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
ClearityFoundationClinicalTrial
GEMCITABINE RAF1

Interaction Score: 0.08

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
21636554

Sources:
PharmGKB
GEMCITABINE ERCC2

Interaction Score: 0.08

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
PharmGKB
GEMCITABINE CASP7

Interaction Score: 0.08

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
22441531

Sources:
PharmGKB
GEMCITABINE CDKN2A

Interaction Score: 0.07

Interaction Types & Directionality:

n/a

Interaction Info:

combination therapy PD0332991 + Gemcitabine

Indication/Tumor Type pancreatic cancer

Response Type decreased response

PMIDs:
25156567

Sources:
JAX-CKB
GEMCITABINE TGM2

Interaction Score: 0.07

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
17079475

Sources:
NCI
GEMCITABINE SERPINC1

Interaction Score: 0.07

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
31616045

Sources:
PharmGKB
GEMCITABINE NRG1

Interaction Score: 0.06

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
23390248

Sources:
CIViC
GEMCITABINE BRCA2

Interaction Score: 0.06

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
29338080

Sources:
CIViC
GEMCITABINE CYP2C8

Interaction Score: 0.06

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
31616045

Sources:
PharmGKB
GEMCITABINE KRAS

Interaction Score: 0.06

Interaction Types & Directionality:

n/a

Interaction Info:

Indication/Tumor Type biliary tract cancer

combination therapy Panitumumab + Gemcitabine + Oxaliplatin

Approval Status Phase Ib/II

PMIDs:
26540314 27975152 26091808 26156229 27167172 26228206 24915778 21862683

Sources:
JAX-CKB CIViC
GEMCITABINE HRAS

Interaction Score: 0.05

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
16818479

Sources:
NCI
GEMCITABINE CHEK1

Interaction Score: 0.05

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
17245119

Sources:
NCI
GEMCITABINE NRAS

Interaction Score: 0.03

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
21636554

Sources:
PharmGKB
GEMCITABINE BRCA1

Interaction Score: 0.03

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
12684687 29338080

Sources:
NCI CIViC
GEMCITABINE SRC

Interaction Score: 0.03

Interaction Types & Directionality:

n/a

Interaction Info:

combination therapy Bosutinib + Gemcitabine

Indication/Tumor Type biliary tract cancer

Response Type sensitive

PMIDs:
27196758

Sources:
JAX-CKB
GEMCITABINE ESR2

Interaction Score: 0.03

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
22838950

Sources:
PharmGKB
GEMCITABINE FGFR3

Interaction Score: 0.02

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
29941343

Sources:
CIViC
GEMCITABINE TNF

Interaction Score: 0.02

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
31616045

Sources:
PharmGKB
GEMCITABINE PTEN

Interaction Score: 0.02

Interaction Types & Directionality:

n/a

Interaction Info:

combination therapy Gemcitabine + LY2780301

Indication/Tumor Type breast adenocarcinoma

Response Type sensitive

PMIDs:
28750271

Sources:
JAX-CKB
GEMCITABINE ERBB2

Interaction Score: 0.02

Interaction Types & Directionality:

n/a

Interaction Info:

Evidence Type Actionable

Approval Status Phase II

Response Type predicted – sensitive

PMIDs:
15581051

Sources:
JAX-CKB NCI
GEMCITABINE EGFR

Interaction Score: 0.01

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
22285168 21783417

Sources:
PharmGKB
GEMCITABINE ABCG2

Interaction Score: 0.01

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
PharmGKB
GEMCITABINE TP53

Interaction Score: 0.01

Interaction Types & Directionality:

n/a

Interaction Info:

combination therapy MK-1775 + Gemcitabine

Indication/Tumor Type sarcoma

Response Type sensitive

PMIDs:
27815358 27167172 26228206 21389100 23520471

Sources:
JAX-CKB
GEMCITABINE KDR

Interaction Score: 0.01

Interaction Types & Directionality:

n/a

Interaction Info:

combination therapy VEGFR2-169 + Gemcitabine

Indication/Tumor Type pancreatic cancer

Response Type sensitive

PMIDs:
19930156

Sources:
JAX-CKB
GEMCITABINE PIK3CA

Interaction Score: 0.01

Interaction Types & Directionality:

n/a

Interaction Info:

combination therapy Cisplatin + Gemcitabine + Sorafenib

Indication/Tumor Type invasive bladder transitional cell carcinoma

Response Type predicted – resistant

PMIDs:
28750271

Sources:
JAX-CKB
GEMCITABINE AKT1

Interaction Score: 0.01

Interaction Types & Directionality:

n/a

Interaction Info:

combination therapy Cisplatin + Gemcitabine + Sorafenib

Indication/Tumor Type invasive bladder transitional cell carcinoma

Response Type predicted – resistant

PMIDs:
None found

Sources:
JAX-CKB
GEMCITABINE IDH1

Interaction Score: 0.0

Interaction Types & Directionality:

n/a

Interaction Info:

combination therapy Gemcitabine + Radiotherapy

Indication/Tumor Type malignant glioma

Response Type predicted – sensitive

PMIDs:
26853339

Sources:
JAX-CKB

TdgClinicalTrial: GEMCITABINE
- Version: January-2014
Alternate Names:

Drug Info:

Drug Indications antineoplastic agent

Drug Class Small Molecule

FDA Approval approved

Publications:

NCI: GEMCITABINE

Version: 14-September-2017

Alternate Names:

C961 NCI drug code

Drug Info:

Publications:

Matthews et al., 2007, Pharmacological abrogation of S-phase checkpoint enhances the anti-tumor activity of gemcitabine in vivo., Cell Cycle

Fedier et al., 2003, The effect of loss of Brca1 on the sensitivity to anticancer agents in p53-deficient cells., Int. J. Oncol.

Safran et al., 2004, Herceptin and gemcitabine for metastatic pancreatic cancers that overexpress HER-2/neu., Cancer Invest.

DTC: GEMCITABINE
- Version: 02-September-2020
Alternate Names:

CHEMBL888 ChEMBL Drug ID

Drug Info:

Publications:

Labroli MA et al., 2014, The identification of novel 5'-amino gemcitabine analogs as potent RRM1 inhibitors., Bioorg Med Chem

JAX-CKB: Gemcitabine

Version: 27-September-2017

Alternate Names:

Drug Info:

Publications:

Kim et al., 2016, Gemcitabine Plus Radiation Therapy for High-Grade Glioma: Long-Term Results of a Phase 1 Dose-Escalation Study., Int. J. Radiat. Oncol. Biol. Phys.

Osborne et al., 2016, Multiparameter Lead Optimization to Give an Oral Checkpoint Kinase 1 (CHK1) Inhibitor Clinical Candidate: (R)-5-((4-((Morpholin-2-ylmethyl)amino)-5-(trifluoromethyl)pyridin-2-yl)amino)pyrazine-2-carbonitrile (CCT245737)., J. Med. Chem.

Kreahling et al., 2013, Wee1 inhibition by MK-1775 leads to tumor inhibition and enhances efficacy of gemcitabine in human sarcomas., PLoS ONE

PharmGKB: gemcitabine

Version: 18-August-2020

Alternate Names:

Drug Info:

Publications:

Knights J et al., 2014, Genetic factors associated with gemcitabine pharmacokinetics, disposition, and toxicity., Pharmacogenet Genomics

Woo HI et al., 2012, Effect of genetic polymorphisms on therapeutic response and clinical outcomes in pancreatic cancer patients treated with gemcitabine., Pharmacogenomics

Björn N et al., 2020, Genes and variants in hematopoiesis-related pathways are associated with gemcitabine/carboplatin-induced thrombocytopenia., Pharmacogenomics J

CIViC: GEMCITABINE

Version: 14-September-2020

Alternate Names:

Drug Info:

Publications:

McCaffery I et al., 2013, Putative predictive biomarkers of survival in patients with metastatic pancreatic adenocarcinoma treated with gemcitabine and ganitumab, an IGF1R inhibitor., Clin Cancer Res

O'Reilly EM et al., 2018, Phase 1 trial evaluating cisplatin, gemcitabine, and veliparib in 2 patient cohorts: Germline BRCA mutation carriers and wild-type BRCA pancreatic ductal adenocarcinoma., Cancer

Sun et al., 2009, Polymorphisms in XRCC1 and XPG and response to platinum-based chemotherapy in advanced non-small cell lung cancer patients., Lung Cancer

TTD: Gemcitabine
- Version: 2020.06.01
Alternate Names:

D03UVS TTD Drug ID

Drug Info:

Publications:
ChemblDrugs: chembl:CHEMBL888
- Version: ChEMBL_27
Alternate Names:

Drug Info:

Publications:
ClearityFoundationClinicalTrial: GEMCITABINE
- Version: 15-June-2013
Alternate Names:

Drug Info:

Publications:
ClearityFoundationBiomarkers: GEMCITABINE
- Version: 26-July-2013
Alternate Names:

Drug Info:

Publications:

Trial Name	gemcitabine HCl,Gemzar
Novel drug target	Established target

Evidence Type	Actionable
Approval Status	Preclinical
Response Type	decreased response

Evidence Type	Emerging
Approval Status	Preclinical - Cell line xenograft
Response Type	predicted – sensitive

combination therapy	Gemcitabine + Radiotherapy
Indication/Tumor Type	malignant glioma
Response Type	predicted – sensitive

combination therapy	PD0332991 + Gemcitabine
Indication/Tumor Type	pancreatic cancer
Response Type	decreased response

Indication/Tumor Type	biliary tract cancer
combination therapy	Panitumumab + Gemcitabine + Oxaliplatin
Approval Status	Phase Ib/II

combination therapy	Bosutinib + Gemcitabine
Indication/Tumor Type	biliary tract cancer
Response Type	sensitive

combination therapy	Gemcitabine + LY2780301
Indication/Tumor Type	breast adenocarcinoma
Response Type	sensitive

combination therapy	MK-1775 + Gemcitabine
Indication/Tumor Type	sarcoma
Response Type	sensitive

combination therapy	VEGFR2-169 + Gemcitabine
Indication/Tumor Type	pancreatic cancer
Response Type	sensitive

combination therapy	Cisplatin + Gemcitabine + Sorafenib
Indication/Tumor Type	invasive bladder transitional cell carcinoma
Response Type	predicted – resistant

GEMCITABINE Drug Record

GEMCITABINE chembl:CHEMBL888 ApprovedAntineoplasticImmunotherapy

Alternate Names:

Drug Info:

Publications:

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info:

PMIDs: 16041392 17000136 17565005 15550676 21642870 22838949 22838950 24361227

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 22293537

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 22838950

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 26894380

Sources: CIViC

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 22838950

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 22838950

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 24444404

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 22838950

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 24225399

Sources: PharmGKB

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info: Trial Name gemcitabine HCl,Gemzar Novel drug target Established target

PMIDs: 24588962 16708051 17065054 16966686 17636467 16807441 17131328 23038758 24647522 19543324 24595080 14977831 15217961

Sources: DTC ClearityFoundationBiomarkers TdgClinicalTrial ClearityFoundationClinicalTrial CIViC

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 31616045

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 31616045

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 31616045

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 31616045

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: None found

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 31616045

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 31616045

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 25162786

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 31616045

Interaction Types & Directionality:

inhibitor (inhibitory)

PMIDs:
16041392 17000136 17565005 15550676 21642870 22838949 22838950 24361227

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
22293537

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
22838950

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
26894380

Sources:
CIViC

Interaction Types & Directionality:

n/a

PMIDs:
22838950

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
22838950

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
24444404

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
22838950

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
24225399

Sources:
PharmGKB

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Trial Name gemcitabine HCl,Gemzar

Novel drug target Established target

PMIDs:
24588962 16708051 17065054 16966686 17636467 16807441 17131328 23038758 24647522 19543324 24595080 14977831 15217961

Sources:
DTC ClearityFoundationBiomarkers TdgClinicalTrial ClearityFoundationClinicalTrial CIViC

Interaction Types & Directionality:

n/a

PMIDs:
31616045

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
31616045

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
31616045

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
31616045

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
None found

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
31616045

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
31616045

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
25162786

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
31616045

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
31616045

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
31616045

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
30889042 25162786 18538445

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
22838949

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
21636554

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
26906009

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
31616045

Sources:
PharmGKB

Interaction Types & Directionality:

n/a